Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rogaratinib plus atezolizumab in cisplatin-ineligible FGFR-positive advanced or metastatic urothelial carcinoma
jRCT2080223991Phase 2Completed
- Sponsor
- Bayer
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of rogaratinib and atezolizumab in transitional cell carcinoma (TCC), sponsored by Bayer. Primary endpoints: Maximum tolerated dose and Recommended phase 2 dose. Started Aug 2018; status: completed.
02
Drugs
rogaratinibatezolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2080223991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223991.